- Home
- MKTW vs LITS Comparison
MKTW vs LITS Comparison
Compare MKTW & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | LITS |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 41.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MKTW | LITS |
|---|---|---|
| Price | $17.76 | $1.16 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 243.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 9.92% | N/A |
| EPS Growth | ★ 1183.33 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $512,403,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.91 | N/A |
| P/E Ratio | $7.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.66 | $0.95 |
| 52 Week High | $21.74 | $3.03 |
Technical Indicators
Market Signals| Indicator | MKTW | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 49.54 |
| Support Level | $16.61 | $0.98 |
| Resistance Level | $20.81 | $1.16 |
| Average True Range (ATR) | 1.24 | 0.06 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 53.14 | 52.38 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.